Cagrilintide vs Amycretin
A long-acting amylin analog built for once-weekly dosing and GLP-1 pairing. GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Cagrilintide | Amycretin | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Long-acting amylin analog (acylated peptide) | Unimolecular GLP-1 + amylin receptor agonist (peptide) |
| Receptor | Amylin receptors (calcitonin receptor + RAMP) | GLP-1 receptor + amylin receptors |
| Molecular weight | ~4,408.9 Da | ≈7,900 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Amylin | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Cagrilintide and Amycretin?
- Cagrilintide is an engineered analog based on Amylin; Amycretin is an engineered analog based on Amylin. Cagrilintide signals at Amylin receptors (calcitonin receptor + RAMP); Amycretin signals at GLP-1 receptor + amylin receptors.
- How do the half-lives of Cagrilintide and Amycretin compare?
- The reported circulating half-life of Cagrilintide is ~7 days (159-195 h); Amycretin is ~days (weekly SC dosing). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Amycretin vs Cagrilintide. Or open the interactive comparison tool to add more molecules.